anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Eligible patients will undergo craniotomy for tumor resection. During the tumor resection and when possible, an initial low dose of albumin-bound paclitaxel will be given following sonication. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered. The sonication device will be implanted at the end of the procedure. In phase 1, about two weeks after surgery, patients will undergo sonication and albumin-bound paclitaxel administration with MRI to quantify extent of blood brain barrier opening. Sonication and administration of albumin-bound paclitaxel will continue every 3 weeks until disease progression. The planned albumin-bound paclitaxel starting dose is 40 mg/m2, to be escalated in the absence of significant toxicity up to 260 mg/m2. Blood samples for circulating tumor DNA will also be collected before and after each sonication. In phase 2, pre-sonication carboplatin at AUC 5 will be added to the regimen, with a safety run-in for the first 6 patients.
Oxygen is essential for plant growth and development. Hypoxia occurs in plants due to limited oxygen availability following adverse environmental conditions as well in hypoxic niches in otherwise normoxic environments. However, the existence and functional integration of spatiotemporal oxygen dynamics with plant development remains unknown. In animal systems dynamic fluctuations in oxygen availability are known as cyclic hypoxia. In this study, we demonstrate that cyclic fluctuations in internal oxygen levels occur in young emerging leaves of Arabidopsis plants. Cyclic hypoxia in plants is based on a mechanism requiring the ETHYLENE RESPONSE FACTORS type VII (ERFVII) that are central components of the oxygen-sensing machinery in plants. The ERFVII-dependent mechanism allows precise adjustment of leaf growth in response to carbon status and oxygen availability within plant cells. This study thus establishes a functional connection between internal spatiotemporal oxygen dynamics and developmental processes of plants.
The present invention provides a method for isolating, identifying and cataloging partial messenger RNAs (mRNAs) or gene tags correlating to secreted and non-secreted proteins in a cell or tissue sample. The method requires obtaining a polynucleotide from a cellular homogenate, wherein the polynucleotide encodes the polypeptide and determining the sequence of the polynucleotide and its expression level. In essence, the method consists of two phases: (1) enrichment/purification of membrane-bound mRNA, and (2) sequence analysis. Neither of these processes, if performed independently of each other, would enable specific and rapid identification and enumeration of transcrips that encode secreted proteins and integral membrane bound proteins. This invention also provides computer-related systems and methods. More specifically, the invention provides a system and method for automatically generating a data base of gene tags corresponding to secreted and non-secreted proteins from cell or tissue samples and using the data base for filtering the tag counts from the samples into meaningful candidates for further testing and analysis.
A method of treating and/or preventing lesion and/or inflammation of non-peptic ulcer nature in the digestive tract of an individual and a method of treating and/or preventing lesion and/or inflammation of the oesophageal, gastric and/or duodenal mucosa of an individual. The method comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a salt or complex of a sulfated sucrose, said sucrose salt or sucrose complex being water-soluble at a neutral pH. The sulfated sucrose is at least disulfated and the salt or complex of the sucrose sulfate may be e.g. a salt or a complex with an alkali metal such as sodium or potassium, or an alkaline earth metal. An interesting sucrose sulfate is sodium sucrose octasulfate. The lesion and/or inflammation may e.g. be caused by conditions located in the oesophagus, in the stomach, in the duodenum, in the jejunem or in the ileum, colon or rectum. It may also be conditions caused by fistulae, trauma, enterotoxins, viral infections or microorganisms. Furthermore, the lesion and/or inflammation may be caused by premalignant or malignant diseases.
The present invention applies a modern traditional Chinese medicine production method and uses eucommia bark or twigs and leaves, siberian solomonseal rhizome, haw, black plum and green tea as raw materials to prepare instant eucommia tea with the functions of treating constipation, promoting urination, reducing blood fat, regulating blood pressure, resisting senility, protecting the liver, nourishing the kidney, losing weight and beautifying and a water beverage thereof by means of a supercritical carbon dioxide extraction technology. The production method has the advantages of high extraction efficiency, short extraction time and strong selectivity. The whole operation process does not exceed 50 DEG C. The present invention can prevent effective ingredients from being damaged. The method adopts a high efficiency spray granulation technology. Three process steps including mixing, drying and fine grain preparation are completed in the same device. The present invention has the characteristics of compact equipment, short technological process, high production efficiency, etc.
This randomized, parallel, double-blind, placebo controlled multi-center clinical study was conducted in 396 patients scheduled to undergo elective general anesthesia laparotomy or orthopedic surgery. Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation. At the end of surgical suture, 5mg morphine was injected intravenously, and then the patient-controlled intravenous analgesia pump was connected. Efficacy was assessed by morphine dosage during the first 24 hours, pain intensity score, and area under the pain-time curve after surgery. Safety was assessed by the incidence of adverse events.
Prevention of foot ulcer should result in a reduction in the risk of lower limb amputation. We propose to identify risk factors for diabetic foot ulcer by studying the relationship between endothelial dysfunction and foot ulcer risk. It has been proposed that impaired vasoregulation in diabetic patients leads to the development and perpetuation of chronic foot ulceration via failure of the normal hyperemic response to injury. A fundamental defect that has been demonstrated in type 1 and 2 diabetic subjects is impaired vasodilatory reserve, which reflects dysfunction of endothelium-dependent vasodilation. Our findings thus far point to an important role of the microvasculature in the development of diabetic foot ulcer and amputation, with our demonstration of higher foot ulcer and lower-limb amputation risk in relation to lower dorsal foot transcutaneous oxygen level. The role of endothelial dysfunction in relation to diabetic foot ulcer risk has not previously been studied.

We will follow a well-characterized cohort of 750 diabetic veterans without foot ulcer over 3-year after obtaining baseline measures of endothelial function using iontophoretic application of acetylcholine to induce cutaneous endothelium-dependent vasodilation on the dorsal foot. Iontophoresis permits noninvasive delivery of ionic drugs cutaneously without damage to the skin or systemic effects. Change in microvascular flow will be measured using a laser Doppler imager (Moor LDI) over a 4x4 cm area divided into 18496 measurement sites. Endothelial function will be defined as the difference between readings before and after the iontophoretic application of a 1% acetylcholine solution at a current of 0.2 mA for 1 minute, with higher readings reflecting better endothelial function. These techniques are the accepted standard method for assessment of endothelium-dependent vasodilation in the cutaneous microvasculature. Additional measurements will be obtained on other ulcer risk factors to assess whether endothelial dysfunction independently influences foot ulcer risk, or whether it is merely a marker for different pathophysiologic conditions responsible for higher risk (eg., sensory neuropathy). Possible confounding factors considered will include sensory and autonomic neuropathy; dorsal foot transcutaneous oximetry; macrovascular function assessed with Doppler blood pressures; diabetes characteristics; in-shoe plantar pressure (F-scan), medication use, and foot deformity.
The modified EGFR stratum was defined as patients less heavily pretreated who had received one or two lines of prior therapy, with a documented response to a EGFR tyrosine kinase inhibitor (TKI) (complete response (CR), partial response (PR) or stable disease (SD) for ≥ 6 months), unless the patient had de novo resistance to EGFR TKI. Patients received AUY922 at 70 mg/m\^2 weekly infusions.
The present invention discloses a huafeng pill which is made from 14 kinds of traditional Chinese medicine of perilla leaf, stiff silkworm, scorpion, araceae, atractylodes, realgar, sodium borate, croton cream, musk, borneol, gastrodia elata, schizonepeta spike, sandal and cinnabar by adding medicine mother. Except musk and cinnabar, the 14 kinds of traditional Chinese medicine are taken and pulverized, and are uniformly mixed with medicine mother. Water is used for making pills, then, cinnabar and musk are used for coating, and the finished products are obtained after dryness. The present invention adopts usual traditional Chinese medicine as raw materials, and has the advantage that a fermentation technology is sufficiently absorbed. The present invention has the advantages of relatively low manufacture cost and safe and convenient administration. The present invention has functions of elimination of wind, relief of muscular spasm and elimination of phlegm for resuscitation. The present invention not only can be used for treating diseases of epilepsy, apoplexy and hemiplegia, but also can be used for treating diseases, such as wind phlegm obstruction, facial paralysis, facial hemiparalysis, etc.
Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
The implantation of unicortical cortex screws in the proximal hole of locking compression plates (LCP) has been recommended for proximal interphalangeal (PIP) arthrodesis in horses to prevent fractures resulting from stress risers in the proximal phalanx (P1). However, this cortex screw fixation technique may limit efficient dorsal compression of the PIP joint by the plate, potentially affecting the stability of the construct. In this study, we aimed to measure stress and strain in P1 and the plate using an ex vivo model of PIP arthrodesis in horses. We employed various implantation methods and proximal screw types in conjunction with two 5.5 mm transarticular cortex screws. Ten pairs of equine forelimbs were divided into four groups based on proximal screw placement: GUC (unicortically placed cortex screw), GBC (bicortically placed cortex screw), GUL (unicortically placed locking screw), and GBL (bicortically placed locking screw). We calculated the magnitude and direction of strain, strain ratio, and stress using strain gauges during an axial compression mechanical testing. The palmar surface of P1 exhibited higher stress and strains than the dorsal surface, with the plate part located at the articular level suffered more stress than the proximal part. Both the implantation method and proximal screw type significantly influenced the analyzed parameters. The GUC promoted greater changes in strain direction in the proximal portion of the P1. Bicortical placement of a cortex screw appears to be the most suitable option for filling the proximal hole of the LCP, because it allows effective dynamic compression via the plate and prevents abrupt shifts in the direction of the forces acting on the proximal part of P1 during loading.
<P>PROBLEM TO BE SOLVED: To solve such problems that microorganism products which are produced by conventional techniques as dried granular products are difficult to be uniformly mixed into feed for oxen and horses, because the products are mixed into the feed in a considerably high ratio, and further that other products which are conventionally produced for a considerably long period by aiming to decrease a blending ratio and mixing a dried water-soluble powder into a carrier comprising water are also difficult to be uniformly mixed into the feed, because the products thus produced are formed into liquid drops having an extremely high molecular size and molecular weight and therefore used in such a manner that an amount of the liquid drops actually used for treating the feed is only several drops, for example, about 10 drops of the liquid drops in a large size are only mixed into 1 ton of the feed to be treated.  <P>SOLUTION: A live microorganism product is obtained by suspending microorganisms existing in a dormant state in a substantially anhydrous liquid carrier. The carrier preferably comprises an oil. Further, an adsorbent is preferably mixed into the carrier. The microorganism product is stored, transported in a plastic bag, and sprayed on a target host. The microorganisms are activated by a change in a water content or a pH.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
More experienced physician: endotracheal intubation with video fiberscope Assoc. Dr. The group in which Ersin Köksal performed endotracheal intubation using a video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
PURPOSE: Living alone is increasing and associated with health and social risks. Aphasia compounds these risks but there is little research on how living alone interacts with aphasia. This study is a preliminary exploration of this issue.
METHOD: Five people with aphasia who lived alone participated in two supported semi-structured interviews, with the second interview including sharing an artefact that held significance for living alone with aphasia. Interviews were recorded, transcribed verbatim, and analysed through reflexive thematic analysis.
RESULT: Four themes encompassed meaning-making about living alone with aphasia: relationships and reliance on others; risk, vulnerability, and uncertainty; loneliness and time alone; self-reliance and the need to keep busy. Participants had to continuously manage and renegotiate daily challenges around living alone with aphasia.
CONCLUSION: Living alone increases the risk of loneliness. For people with aphasia, the buffer against loneliness provided by social connection and meaningful activity may be more difficult to achieve because of communication challenges. While experiences vary, reliance on others, managing practical and administrative tasks, and negotiating risks are all important issues when alone. The intersection of living alone, loneliness, and living with aphasia needs more research, and more explicit clinical focus when discussing and planning intervention and support.
The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose \<70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.
NYVEPRIA (pegfilgrastim-apgf) injection is a clear, colorless solution supplied in a prefilled single-dose syringe for manual use containing 6 mg pegfilgrastim-apgf, supplied with a 27-gauge 1/2-inch needle and a BD UltraSafe Plus™ Passive Needle Guard.

The NYVEPRIA syringe plunger stopper and needle cover are not made with natural rubber latex.

NYVEPRIA is provided in a dispensing pack containing one sterile 6 mg/0.6 mL prefilled syringe (NDC 0069-0324-01).

NYVEPRIA prefilled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (6 mg/0.6 mL) for direct administration. Use of the prefilled syringe is not recommended for direct administration for pediatric patients weighing less than 45 kg who require doses that are less than the full contents of the syringe.

Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature for more than 15 days. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard syringe if frozen more than once.
Group A is an experimental group that will receive mindfulness intervention for 4 consecutive weeks. Group A consists of 2-3 cohorts with 10-15 subjects per cohort.
The study is a multi-site, prospective, observational study conducted in 24 hospitals representing different regions across China. The choice of 24 hospitals was based on their representation of diverse geographical regions across China. These hospitals were selected to ensure a comprehensive validation of the screening model's efficacy in varied healthcare settings. Data will be collected through a mobile application, providing real-time prognostic scores for patients. The study is divided into three parts: patient recruitment, in-hospital follow-up, and post-discharge follow-up . Follow-up will last for 3 months. Endpoints will be considered for all-cause death, survival and liver transplantation. The study is planned to enroll 1500 patients from January 2024 to January 2026.
STUDY OBJECTIVE: The aim of this long-term study was to record substance-specific prevalences of illegal use of narcotics despite court-imposed abstinence requirements.
METHODS: Urine assays were obtained by a public health department on the basis of administrative assistance for the probation department of a district court. The individual and valid allocation of these urine samples was ensured using a proven marker system. After postal dispatch, laboratory chemical analyses for narcotics residues were carried out in an external laboratory via enzyme immunoassay and validation by mass spectrography in the case of positive narcotics results. On the basis of all available routine data, a pooled data set covering a total of fourteen consecutive calendar years (2006-2019) was generated digitally and evaluated anonymously.
RESULTS: From a total of 380 subjects (female: 13% versus male: 87%; average age: 30.4 years), 13,500 individual narcotic substance analyses from 2,941 urine samples were available. In 2.7% of all individual analyses, at least one of eight potential narcotic substances was detected, whereby the highest overall prevalences in the sense of a relapse were found for cannabis with 3.7% and for opiates with 2.4%. In contrast, there were almost no residues for barbiturates and LSD and no positive evidence for buprenorphine and PCP. As expected, most relapses in all narcotics groups were found in the age groups from 18 to 35 years. Strikingly, more women than men violated the court abstinence order with amphetamines, while relapses with the other seven narcotics groups occurred predominantly among men. In the course of the entire observation period, the most marked fluctuations in relapse rates were found for cannabis, opiates and cocaine.
CONCLUSION: The use of narcotic substances during probation and parole supervision does not appear to be a rare occurrence and has received little professional attention. Increased attention to this group-specific recidivism and more studies on this topic should help reduce this deficit.
Enrolled healthy newborns with high risk for atopic dermatitis will be 1:1 randomised into treatment and control group. The treatment group receives the SanaCutan Basiscreme for twice daily skin application until the age of 6 months (main phase; half of them until the age of 12 months (main + follow-up phase)), whereas the control group should avoid skin care products. Guardians of both groups are requested to document all applied skin care products in a diary. In regular visits at the study sites, a blinded physician investigates the skin of the children. In case of an atopic dermatitis (= atopic dermatitis has to be diagnosed in at least two visits with an interval of at least four weeks), the severity will be examined (SCORAD) and the treatment with SanaCutan Basiscreme will be terminated. All children will be followed up until the age of 6 months (end of main phase). This is the time when a blood test will be conducted to determine sensitization against food and inhalant allergens and total IgE. If children do not develop an atopic dermatitis in the main phase, the study continues until they receive the diagnosis (up to a maximum of 12 months, end of follow-up phase).
PURPOSE: A method and device for processing medical information are provided to prevent miss matching of medical information. CONSTITUTION: A first digital image which is generate by testing a tested person and a first inherent information of the tested person is received. First inherent information is stored to a server(200). First inherent information of the tested person is displayed in a recognition area set in an area which is a part of the first digital image of the tested person(210). The first inherent information which is displayed on a recognition area of the first digital image is scanned. The first digital image is matched with the first inherent information stored in the server(230). A second digital image which is different from the first digital image is received.
Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
PURPOSE:To provide the subject blood platelet-anticoagulant containing bisdethiodimethylthioacetylaranotin as the active component, showing a remarkable platelet aggregation inhibition and effective for prevention and remedy of thrombosis. CONSTITUTION:A compound of the formula is contained as the active component. The compound of the formula is obtained, e.g. by using Aspergillus terreus GSL-299 strain having an excellent productivity selected from strains separated from soil. Both of oral and parenteral administration are available as the administration method and the dose is suitably 5-300mg/kg in case of oral administration and 0.5-30mg/kg in case of parenteral administration. Tablet, powder, capsule, granule, suppository, injection, etc., are possible as the dosage form.